Therapeutic efficacy evaluation of radioimmunotherapy with 90Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma

Hitomi Sudo, Atsushi B. Tsuji, Aya Sugyo, Tsuneo Saga, Mika K. Kaneko, Yukinari Kato, Tatsuya Higashi

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with 90Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model. 111In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with 90Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of 90Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that 90Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients.

Original languageEnglish
Pages (from-to)1653-1664
Number of pages12
JournalCancer Science
Issue number5
Publication statusPublished - 2019 May


  • antibody
  • malignant mesothelioma
  • podoplanin
  • radiation
  • radioimmunotherapy


Dive into the research topics of 'Therapeutic efficacy evaluation of radioimmunotherapy with 90Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma'. Together they form a unique fingerprint.

Cite this